Cargando…

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis

BACKGROUND: Lymphopenia is a well-known adverse event of fingolimod, a disease-modifying drug for multiple sclerosis (MS). OBJECTIVES: The objective of this paper is to investigate risk factors for predicting fingolimod-induced lymphopenia in MS by frequent hematological monitoring. METHODS: We retr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohtani, Ryohei, Mori, Masahiro, Uchida, Tomohiko, Uzawa, Akiyuki, Masuda, Hiroki, Liu, Jia, Kuwabara, Satoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824911/ https://www.ncbi.nlm.nih.gov/pubmed/29497558 http://dx.doi.org/10.1177/2055217318759692

Ejemplares similares

Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis
por: Masuda, Hiroki, et al.
Publicado: (2020)

Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder
por: Masuda, Hiroki, et al.
Publicado: (2017)

Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSD
por: Masuda, Hiroki, et al.
Publicado: (2023)

Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
por: Masuda, Hiroki, et al.
Publicado: (2022)

Higher longitudinal brain white matter atrophy rate in aquaporin-4 IgG-positive NMOSD compared with healthy controls
por: Masuda, Hiroki, et al.
Publicado: (2023)

Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica
por: Uzawa, Akiyuki, et al.
Publicado: (2010)

Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment
por: Uzawa, Akiyuki, et al.
Publicado: (2022)

Relapse of Neuromyelitis Optica Spectrum Disorder Associated with Intravenous Lidocaine
por: Uzawa, Akiyuki, et al.
Publicado: (2011)

Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal
por: Koska, Valeria, et al.
Publicado: (2021)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Detection of mumps virus RNA in cerebrospinal fluid of patients with neuromyelitis optica
por: Mori, Masahiro, et al.
Publicado: (2011)

Fingolimod: Lymphopenia and COVID-19 infection complicated by pneumonia: case report
Publicado: (2020)

AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2021)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Primary cutaneous cryptococcal infection due to fingolimod – Induced lymphopenia with literature review
por: Patil, Sachin M., et al.
Publicado: (2020)

Multiple Cerebral Infarctions Complicating Deep Vein Thrombosis Associated With Uterine Adenomyosis: A Case Report and Literature Review
por: Tamura, Mitsuyoshi, et al.
Publicado: (2022)

Lymphopenia in treatment-naive relapsing multiple sclerosis
por: Lim, Zhi Wei, et al.
Publicado: (2016)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Increased risk of disseminated cryptococcal infection in a patient with multiple sclerosis on fingolimod
por: Kaur, Pushpinder, et al.
Publicado: (2020)

Disseminated Cryptococcosis in a 63-year-old Patient with Multiple Sclerosis Treated with Fingolimod
por: Seto, Hiroyuki, et al.
Publicado: (2016)

Peripheral Blood T Cell Dynamics Predict Relapse in Multiple Sclerosis Patients on Fingolimod
por: Song, Zi-Ye, et al.
Publicado: (2015)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
por: Marriott, James J.
Publicado: (2011)

Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients
por: Farrokhi, Mehrdad, et al.
Publicado: (2015)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2017)

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis
por: Bascuñana, Pablo, et al.
Publicado: (2020)

Disseminated Histoplasmosis in a Patient With Multiple Sclerosis Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021)

Modulation of Tregs and iNKT by Fingolimod in Multiple Sclerosis Patients
por: Ferraro, Diana, et al.
Publicado: (2021)

Fingolimod‐induced bladder lymphoma in a patient with multiple sclerosis
por: Vaheb, Saeed, et al.
Publicado: (2023)

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023)

Severe Subcutaneous Calcification in an Interferon-β-treated MS Patient
por: Masuda, Hiroki, et al.
Publicado: (2017)

Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
por: Sharma, Sushil, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hvnk8f2q69cpgs7n7oef911k12